- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 128,98 | -0,05 % | Gilead wins favorable U.S. label update for Yescarta | ||
| ZOETIS | 108,12 | +0,30 % | Zoetis Inc. - 8-K, Current Report | ||
| INCYTE | 91,10 | -0,65 % | Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? | ||
| CASSAVA SCIENCES | 1,743 | +1,22 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| AMARIN | 12,500 | 0,00 % | Amarin Corporation plc: Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company's VASCEPA/VAZKEPA (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization | DUBLIN and BRIDGEWATER, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 160,00 | 0,00 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 3,385 | -5,97 % | Achieve Life Sciences: Entscheidet der 20. Juni über Leben und Tod? | Seit unseres Trading-Tipps im Juli letzten Jahres konnte die Aktie von Achieve Life Sciences zwischenzeitlich über +150% zulegen, korrigierte in den letzten Wochen aber wieder um mehr als 20%. Das Unternehmen... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 401,30 | -0,62 % | Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth | ||
| ANI PHARMACEUTICALS | 68,50 | -1,44 % | Aktien New York: Dow stabilisiert sich - S&P 500 setzt Rekordkurs fort | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Montag ihre anfänglich moderaten Verluste im Handelsverlauf aufgeholt und tendieren leicht im Plus. Zunächst hatte der sich weiter zuspitzende Streit... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,050 | 0,00 % | Enzon Pharmaceuticals, Inc: Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger | CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) ("Enzon" or the "Company"), today announced that it has commenced an exchange offer (the "Offer") involving... ► Artikel lesen | |
| TALPHERA | 0,683 | -0,87 % | Talphera, Inc.: Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update | Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc.
Cash and investments at September 30, 2025 were $21.3 million; combined... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 29,000 | 0,00 % | RIGEL PHARMACEUTICALS INC - 8-K, Current Report | ||
| SAVARA | 4,440 | +2,78 % | Savara Inc.: Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* | -- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 1,260 | -3,08 % | Biodexa Pharmaceuticals PLC: Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST | February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models... ► Artikel lesen | |
| ARTIVION | 33,250 | -0,75 % | The Analyst Verdict: Artivion In The Eyes Of 4 Experts |
CORNERSTONE THERAPEUTICS INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.